Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 9/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 9/20 | 1.00 |
| ▸ | MET | P08581 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | YES1 | P07947 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pha-665752 SCHEMBL29376386 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93656 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93657 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL140412 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL93654 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL15639801 | 0.99 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| Pha-665752 SCHEMBL15639803 | 0.99 | KDR (0.99) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL23691031 | 0.97 | KDR (0.94) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL143795 | 0.96 | KDR (0.93) | KDRFGFR1PDGFRBMETSRC | |
| SCHEMBL147331 | 0.95 | KDR (0.91) | KDRFGFR1PDGFRBMETSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| CN-113164480-B | Pharmaceutical composition for treating diffuse gastric cancer | 学校法人金泽医科大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-113164480-A | Pharmaceutical composition for treating diffuse gastric cancer | 学校法人金泽医科大学 | 2021-07-23 | — | — | CN | disclosed |
| CN-104762371-B | Biomarkers for predicting or monitoring the efficacy of c-Met inhibitors | 三星电子株式会社 | 2021-03-09 | — | — | CN | disclosed |
| US-20210047618-A1 | Improved Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2021-02-18 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2012028334-A2 | MARKER FOR SUNITINIB RESISTANCE FORMATION | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426213-A1 | Marker for sunitnib resistance formation | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | KDR 953/4885FGFR1 1911/4885PDGFRB 1100/4885 |
| US-20210047618-A1 | Improved Differentiation Method | VIPR2, IAPP, PROX1 | KDR 3019/4885FGFR1 2149/4885PDGFRB 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.